Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for gastrointestinal, foodborne, viral, respiratory, and parasitic infectious diseases. The company’s diagnostic products primarily consist of C. difficile for the detection of gastrointestinal diseases; Rotavirus and Adenovirus products for pediatric diarrhea detection; H. pylori for stomach ulcers; Enterohemorrhagic E. coli infection and Campylobacter jejuni used in the detection of foodborne diseases; Varicella-Zoster for viral diseases; and Cytomegalovirus for organ transplant infections. Its products also include transport media that store and preserve specimen samples from patient collection to laboratory testing. The company’s diagnostic test kits utilize immunodiagnostic and molecular technologies, which test samples of stool, blood, urine, and other body fluids or tissue for the presence of specific infectious diseases. In addition, Meridian Bioscience, Inc. manufactures and distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic manufacturers. Further, it involved in the contract development and manufacture of proteins and other biologicals under cGMP conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The company sells its diagnostic test kits through direct sales force and independent distributors to reference laboratories and hospitals, principally in the United States, Canada, Belgium, France, Holland, Italy, the United Kingdom, Africa, the Middle East, and other European countries. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.